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Chronic kidney disease (CKD) is associated with an imbalanced human microbiome due not 
only to CKD-associated factors such as uremia, increased inflammation and 
immunosuppression, but also to pharmacological therapies and dietary restrictions. End-stage 
renal disease patients require renal replacement therapies commonly in the form of 
hemodialysis (HD) or peritoneal dialysis (PD). HD implies the existence of a vascular access, 
such as an arteriovenous fistula/graft or a venous catheter, whereas PD implies a long-term 
peritoneal catheter and the constant inflow of peritoneal dialysate. Also, dietary adaptations are 














HD and PD appear to be associated with different changes in the gut microbiome, for example 
a decrease in Proteobacteria relative abundance in HD patients and increase in PD patients. 
Both therapies may also have an impact on the human microbiome beyond the gut, leading to 
increased relative abundance of specific bacteria in the blood microbiome of HD patients and 
increased relative abundance of other bacteria in the peritoneal microbiome of PD patients. HD 
and PD catheter biofilms may also play an important role in the changes observed in these 
microbiomes.  
A more interdisciplinary approach is needed to further clarify the role of microbial groups other 
than bacteria in all body habitats to allow the complete understanding of the impact of HD or 
PD on the microbiome of CKD patients. Moreover, strategies that promote a healthy balance 
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The term human microbiome was firstly defined by Lederberg & McCray [1] as the collection 
of all symbiotic, commensal and pathogenic microorganisms living in association with the 
human body. It is currently estimated that human microbiome encompasses 10 times more cells 
and 100 times more genes than the host, and includes a range of organisms, such as bacteria, 
archaea, fungi, protozoa and viruses [2]. The human microbiome is considered by some authors 
a metabolically active endogenous “organ” in itself [2-4] that influences the well-being of the 
host by contributing to its nutrition, metabolism, physiology and immune function [2, 5-7]. The 
microbiome is now described as a central part of human health. Therefore, it is essential to 
study its composition and take advantage of the continuous improvement of technology to 
increase the existing knowledge on microorganisms-host interaction and its role in disease 
development.   
Each individual harbors a unique microbiome with differences in species, abundance and 
diversity of the microbial communities in various body sites [8]. Much of this diversity found 
between individuals has been attributed to differences in host genetics, geographical origin, 
age, lifestyle, dietary habits, and exposure to antibiotics [8, 9]. In healthy individuals, 
Bacteroidetes and Firmicutes contribute to 49% of all species of the so far characterized human 
microbiome, being Actinobacteria, Proteobacteria and Verrucomicrobia in a second line of 
colonization [10].  
The homeostasis of the human microbiome is largely dependent on environmental conditions 
and, therefore, this complex system is greatly influenced by health and disease states and the 
subsequent therapeutic strategies used. One of the most well studied microbiome is the gut 
microbiome. Disturbances of the normal gut microbiome, known as gut dysbiosis, are currently 
recognized in the pathogenesis of diverse chronic diseases, such as obesity [11, 12], insulin 
resistance and diabetes [13-15], inflammatory bowel disease [16], liver cirrhosis [17], 
myocardial ischemia [18], cancer [19] and neuronal disorders [20-22]. Gut dysbiosis has also 
been reported in chronic kidney disease (CKD), in either humans or animal models [23-31]. 
The effect of some therapeutics on microbial composition has been intensively studied. For 
instance antibiotics induce long-term decreases in bacterial diversity and their effects may be 
hard to reverse [10, 32] and corticosteroids and immunosuppressive agents were also shown to 
disrupt microbial networks in allograft recipients [33, 34]. Moreover, diet strongly influences 
the composition of human microbiome in a way we are just now starting to understand [18]. 
End-stage renal disease (ESRD) patients are a complex group of patients with many 













frequently antibiotherapy and appropriate diet recommendations, as the avoidance of sodium 
and phosphate-rich foods [35]. The most common renal replacement (RRT) therapies, 
hemodialysis (HD) and peritoneal dialysis (PD), present particularities that may have a further 
impact on the human microbiome. Hemodialysis implies the existence of a vascular access, in 
the form of an arteriovenous fistula/graft or a venous catheter, and strict dietary restrictions, as 
limitation of potassium intake. Peritoneal dialysis implies a long-term peritoneal catheter and 
the constant inflow of peritoneal dialysate containing a primary microbial nutrient, glucose, as 
well as sodium, chloride, calcium and lactate (or bicarbonate) [36]. Therefore, in this review, 
we will explore the influence of the RRTs, HD and PD, on the human microbiome of ESRD 
patients. 
 
2. Chronic kidney disease and renal replacement therapies 
Due to the increasing number of patients, CKD is currently considered a public health problem 
worldwide [37]. CKD has a complex etiology involving both an inherited predisposition and 
exposure to environmental factors [38, 39]. Within health determinants, the most common 
causes of CKD worldwide are diabetes and hypertension [37]. Cardiovascular (CV) disease is 
the major cause of death in CKD patients. Although the life expectancy of patients with ESRD 
markedly improved since the introduction of RRT in the 1960s, it remains lower than that of 
the general population [40]. When compared to patients on HD or PD, kidney transplant 
recipients present reduced CV events and mortality as well as a superior quality of life. 
However, kidney transplantation as a RRT cannot be performed in all ESRD patients due 
associated comorbidities and lack of suitable donors. Therefore most patients with ESRD are 
submitted to dialysis during their lifetime, either HD or PD [41].  
Several nutritional guidelines are followed by CKD patients depending on the existence and 
type of RRT and are mainly focused on protein, energy and ion requirements [42, 43]. The 
dietary intake recommendations for CKD patients, with and without dialysis therapy are 
summarized in table 1[42, 44]. 
In patients undergoing HD, the incidence of vascular access-related infections varies among 
medical facilities and is closely related to the type of vascular access used, being lowest in HD 
patients with arteriovenous fistulas or arteriovenous grafts and highest in patients with tunneled 
and non-tunneled Central Venous Catheters (CVCs) [45, 46]. In HD patients, catheter-related 
bacteremia can have two sources: 1) migration from the skin to the exterior of the catheter and 
from there to the bloodstream, and 2) direct inoculation from a biofilm growing on the inner 













related bloodstream infections is Staphylococcus aureus, followed by coagulase-negative 
staphylococci [45, 48]. Together they account for 40-80% of cases in most studies [49]. In 
addition, S. aureus bacteremia is associated with significant morbidity and mortality. Non-
staphylococcal dialysis CVC-related bacteremia is due predominantly to enterococci and 
Gram-negative rods [49]. HIV-positive dialysis patients are more likely to develop 
polymicrobial infections and infections due to Gram-negative and fungal pathogens [50]. 
Gram-negative organisms account for 30-40% of all episodes of catheter-related bacteremia 
and 10-20% of episodes were polymicrobial in several case series [51]. Besides septicemia, 
other infections also frequently occur in HD patients such as pulmonary, gastrointestinal, 
genitourinary and soft-tissue infections [52]. 
Peritonitis and exit-site/tunnel infections are the most relevant PD-related infections and these 
complications remain the Achilles’ heel of the technique, being responsible for catheter loss, 
transfer to HD, prolonged hospitalization and, in more serious cases, death [53]. Thus, 
prevention of PD-related infections is critical to the success of the program. Peritonitis in PD 
patients are frequently caused by single microorganisms, being Gram-positive bacteria 
responsible for 65% of the cases followed by Gram-negative bacteria (15 to 24%) and fungi 
(1.5% to 5%) [49, 54-57]. Within Gram-positive bacteria, the most common are coagulase-
negative staphylococci, S. aureus and Streptococcus spp.. Gram-negative organisms are more 
likely to promote more severe infections with poor outcomes [45]. Pseudomonas sp. is 
probably the most important cause of severe Gram-negative peritonitis in patients undergoing 
PD [45]. Although fungal peritonitis are less frequent, they represent a clinical challenge due 
to its difficult resolution. In addition, a fraction of 11 to 21% of PD-related peritonitis may be 
caused by multiple organisms [49, 54, 56, 57]. 
Few studies described the microorganisms responsible for exit-site infections. A study by 
Scalamogna et al. [58] reported the following organisms, in diminishing order of frequency 
from 102 exit-site infection episodes: S. aureus, Staphylococcus epidermidis, Escherichia 
coli,  Pseudomonas aeruginosa, Serratia marcescens and Enterobacter cloacae. A more recent 
study evaluating 34 exit-site infection episodes reported P. aeruginosa as the most common 
infective organism, responsible for 58.8% of the cases. S. aureus was isolated in 29.4% of the 
cases, and Klebsiella, E. coli and Serratia species in 12% of the cases [59].  Topical application 
of antimicrobial agents such as mupirocin, gentamicin and polysporin triple ointment have 
been successfully used to prevent infections [60, 61].  
The complete list of factors responsible for PD-related infections remains not fully understood, 













with skin-related bacteria [62-64]. Some pathogens may colonize the catheter’s exit-site and 
tunnel during the connection and disconnection procedures of the dialysis transfer-set.  
The existence of biofilms on peritoneal catheters was demonstrated long ago from skin-
associated bacteria [65, 66]. PD-catheter biofilms are formed by common Gram-positive and 
Gram-negative bacteria and are frequently associated with clinical peritonitis. Microbial 
biofilms may persist on the catheter surface, even in the absence of infection, suggesting that 
it may act as a reservoir of infectious agents; for a review see [67].  
Microorganisms colonizing the catheter exit-site can also be associated with peritonitis, but 
curiously only in a very low percentage of patients [68-70]. Catheter replacement can be 
sometimes ineffective in preventing subsequent episodes of peritonitis, suggesting other 
sources of infection [45]. Therefore, alternative routes and factors have been recognized as 
responsible for peritonitis in PD patients, such as transvisceral microbial migration through the 
impaired intestinal barrier (e.g., bowel leak), hematogenous and vaginal leak [71]. Previous 
reports described bacterial DNA in PD effluent or peritoneum cells what supports this 
hypothesis [72-75]. In addition, the intracellular viability of S. aureus after sequestration by 
mesothelial cells was revealed in different studies, supporting this hypothesis [76, 77]. Lately, 
the description of the blood microbiome in a non-infectious state added more clues to the 
limitations affecting PD technique [78-82]. Together these studies reinforce the need to explore 
the human microbiome in PD patients. This is not only necessary to fully understand the impact 
of microorganisms in the correct implementation of this RRT technique, but also to identify 
and limit all routes of infection in these patients.  
 
3. The human microbiome and renal disease  
 
3.1 The microbiome in CKD 
As already stated, gut dysbiosis is well described in CKD [23-31]. This intestinal microbial 
imbalance occurs either quantitative and qualitatively, being frequently associated with the 
overgrowth of Enterobacteriaceae, Lachnospiraceae and some Ruminococcaceae, and with the 
reduction of some Bacteroidaceae, Prevotellaceae and particular Bifidobacterium and 
Lactobacillus species [31]. CKD associated factors may play a role in the promotion of gut 
microbiota imbalance, such as increasing the intestinal availability of uremic toxins, metabolic 
acidosis, intestinal wall edema and reducing the colonic transit and digestive capacity. 
Pharmacological therapies (e.g., antibiotics and iron deliver) and dietary restrictions (e.g. 













[31]. Within the intestinal epithelia, commensal bacteria compete with pathogens for epithelial 
adhesion sites and nutrients. In a dysbiotic state this natural defense is reduced, consequently 
increasing CKD patients’ vulnerability to pathogen invasion. 
Gut dysbiosis itself plays a role in CKD progression and it is starting to be recognized as a non-
traditional factor for CV risk in CKD patients [31]. For example, gut microbiome-produced 
metabolic compounds, such as indoxyl sulfate, p-cresol sulfate, and trimethylamine N-oxide 
(TMAO), are associated with the promotion of CV events [3, 18, 83-86]. Uremia is also 
associated to immune dysfunction characterized by immunodepression in CKD patients, 
contributing to a high prevalence of infections, increased inflammation and CV risk; for a 
review see [87]. Moreover, ammonia derived from metabolization of urea by microbial urease, 
was shown to cause a massive disruption of the intestinal epithelial barrier structure and 
function [88-92], allowing the translocation of gut derived uremic toxins, endotoxin, antigens 
and intestinal microorganisms or other microbial products into circulation [3, 88, 90-94]. This 
‘atopobiosis’ (phenomenon describing the microbes that appear in places other than their 
normal location) is for long recognized as an important route of endogenous infections, but 
more recently has been associated to the dynamics of a variety of inflammatory diseases [78]. 
The pathophysiological mechanisms underlying the role of gut dysbiosis in CKD were deeply 
explored in a previous review [31].  
Although several researchers studied the role of the gut microbiome on CKD progression and 
increased CV risk, a more interdisciplinary approach is still needed in order to clarify the role 
of each microorganism in the development and progression of kidney diseases. Information 
regarding other microbial habitats in human body, as well as better characterization of other 
microbial groups such as archaea, fungi and virus, may also be relevant to understand the 
complete role of microorganisms in CKD pathophysiology.  
 
3.2 The microbiome in HD  
Until now, very few studies compared the gut microbiome in HD and other RRT. However, it 
can be assumed that the existing specificities of this dialysis type naturally influence the 
intestinal microbiota of ESRD (Figure 1). Besides the obvious influence of the vascular access, 
a portal of entrance of microorganisms, HD patients have specific nutritional restrictions as 
potassium in comparison to PD patients, as previously described. Corroborating this hypothesis 
is the study conducted recently by Crespo-Salgado et al. [95] that compared the gut microbiome 
of pediatric patients undergoing PD, HD and post-kidney transplant and healthy controls. 













in HD patients compared to healthy controls. In addition, Proteobacteria was significantly 
decreased in HD patients when compared to PD patients. Regarding the α-diversity levels, the 
gut microbiome of HD patients was similar to controls, having higher diversity than PD 
patients. Although HD patients have significantly increased levels of the uremic toxins indoxyl 
and p-cresyl sulfates, no differences were observed in the taxa usually associated to the 
production of these toxins, namely Bifidobacteriaceae, Clostridiaceae, Enterobacteriaceae and 
Lactobacillaceae [95].  
Other study analyzed the gut microbiome of ESRD patients during HD therapy and compared 
it with healthy persons, reporting an increase of Proteobacteria (primarily 
Gammaproteobacteria), Actinobacteria and Firmicutes (especially subphylum Clostridia) by 
phylogenetic microarrays [28]. However, because there was no comparison to CKD patients 
not undergoing HD, the findings can be a consequence of HD or CKD itself (or both). 
A recent study carried out on HD patients analyzed the effect of a single dose of oral 
vancomycin (250mg) in the gut microbiome of these patients, together with the plasma levels 
of uremic toxins indoxyl and p-cresyl sulfates [96]. As expected, the microbial taxonomic 
richness of fecal samples decreased after vancomycin administration and the effect persisted 
for 4 weeks. Enterobacteriaceae, Lachnospiraceae and particularly the genus Blautia decreased 
on 7th day and returned to or above baseline at 28th day after vancomycin administration, 
coinciding with the decline and subsequent rebound of plasma indoxyl sulfate concentrations. 
Regarding p-cresyl sulfate levels, vancomycin also induced its decrease in the plasma. This 
result could be explained by suppression of specific tryptophan or tyrosine degrading 
microbiota and/or by an increase in competing taxa that bloomed in the vancomycin-perturbed 
gut [96]. However, the recovery of uremic toxin levels 28 days after vancomycin 
administration suggests resilience of the taxa responsible for its generation in ESRD patients. 
Enterococcaceae, Bacteroidales and the genus Bilophila also diminished significantly 
following treatment (7 days after), while Veillonellaceae increased. There was a continued 
significant decrease in Clostridiales and Lachnospiraceae (Roseburia sp.) even 28 days after 
the vancomycin administration. 
Besides the gut, other microbiomes have been characterized in the HD population. Bossola and 
colleagues [97]analyzed blood DNA by 16S rRNA gene PCR amplification, followed by 
amplicons purification and sanger sequencing and showed that 20.7% of 58 HD patients 
presented bacterial DNA in their whole blood samples obtained either from the peripheral vein 
or from the central venous catheter or the arteriovenous fistula, in contrast to the absence of 













E. coli, S. aureus, P. aeruginosa, S. epidermidis, E. faecalis, Proteus mirabilis, and 
Staphylococcus haemolyticus. Moreover, blood cultures of HD patients and healthy controls 
were all negative for bacterial growth, suggesting very low levels of microbial load (not 
detected by this methodology) or lack of microbial viability. In addition, these authors 
associated the circulating bacterial-derived DNA found in HD patients with higher levels of 
inflammatory markers such as high-sensitivity C-reactive protein (CRP) and IL-6. More 
recently, Shi et al. [98] explored the blood microbiome of 22 HD patients and compared to 30 
ESRD non-dialysis patients and 10 healthy controls using next-generation sequencing. Blood 
microbiome was found in 27%, 20% and 0% of HD, ESRD non-dialysis and controls, 
respectively. The bacterial blood colonization within ESRD patients (HD and non-dialysis 
patients) was similar, being Firmicutes, Bacteroidetes and Proteobacteria the dominating 
bacteria phylum. At the genus level, the prevalent bacteria common in both groups were 
Escherichia-Shigella, Prevotella, Faecalibacterium, Bacteroides, and Ruminococcus. 
However, in comparison to ESRD non-dialysis patients, HD patients showed greater 
complexity at the species level that was correlated with higher levels of CRP and endotoxins, 
and elevated gut permeability. The authors suggested that the bloodstream bacteria mainly 
originate from the ESRD dysbiotic gut microbiome and the HD, to some extent, aggravates 
microinflammation in these patients via promotion of gut microbiota translocation due to the 
gut barrier impairment. Although with a limited number of patients, other studies showed 
bacterial DNA in the whole blood of dialysis patients without signs of active infection [99-
101].  
The periodontal microbiome of HD patients was characterized in a 2015 pilot study focused 
on the high prevalence of periodontitis in these patients [102]. No major differences were 
observed in the subgingival microbiome between ESRD and control individuals, but Prevotella 
gingivalis and Tannerella forsythia appeared among the most abundant periodontitis-related 
phylotypes in a subgroup of patients with greater periodontitis extent. The authors highlighted 
the negative correlation between dialysis vintage and microbial diversity within the ESRD 
group. In addition, it was suggested that widespread and localized forms of periodontitis could 
be associated with different microbiomes, particularly if comparing some specific OTUs [102]. 
Moreover, Kshirsagar et al. [103] described a moderate-to-severe periodontal disease strongly 
associated with CV mortality in HD patients. Other studies have associated the oral 
microbiome to the onset of systemic diseases, such as atherosclerosis [104], insulin resistance 















3.3 The microbiome in PD 
As PD is not a frequent option of RRT, studies in these patients’ population are also scarce. To 
our knowledge, there are only two studies evaluating the gut microbiome in PD patients. As 
mentioned above, the gut microbiome of pediatric patients (from 2 to 18 years old) undergoing 
PD or HD and age-matched healthy controls was compared, showing the α-diversity 
significantly decreased in PD patients using both phylogenetic and non-phylogenetic diversity 
measures [95]. The loss of bacterial biodiversity is the most frequent result following intestinal 
dysbiosis [107] and it has been described for infants with necrotizing enterocolitis [108], 
inflammatory bowel disease [109], colorectal cancer [110] and CKD [31]. 
Pediatric PD patients showed relative lower abundance of gut bacteria within the Firmicutes 
and Actinobacteria, whereas the Proteobacteria were significantly increased [95]. The higher 
levels of Proteobacteria (iron oxidizing bacteria) could be associated with the oral iron 
supplementation of PD patients (HD patients receive it directly through the bloodstream). Also, 
PD patients have increased intestinal absorption of glucose from the PD dialysate that promotes 
glucose fermentable bacteria, such as the Enterobacteriaceae [95]. Taking into consideration 
the translocation of gut microbiota to the peritoneal cavity, the increase in intestinal 
Enterobacteriaceae may be responsible for the development of peritonitis in PD patients. Note 
that members of the Enterobacteriaceae family account for up to 12 % of all peritonitis episodes 
in these patients [111].  
In another study, Wang et al. [112] compared adult PD patients and control individuals by 
species-specific real-time PCR. They described a decrease of gut Firmicutes and 
Actinobacteria, especially Bifidobacterium catenulatum, Bifidobacterium longum, 
Bifidobacterium bifidum, Lactobacillus plantarum and Lactobacillus paracasei in adult PD 
patients [112]. In general, CKD patients showed lower intestinal colonization by Lactobacillus 
and Bifidobacterium species [31]. These bacteria are normal colonizers of the human gut and 
play a critical and beneficial role by inhibiting the growth of pathogens through the production 
of acetic acid and lactic acid, lowering the pH in the intestinal milieu and competing with 
pathogens that could colonize the gut mucosa for epithelial adhesion sites and nutrients [113, 
114]. Both groups participate actively on the regulation of intestinal microbial homeostasis and 
may help to reduce the rate of constipation - these bacteria are rarely isolated on adults with 
chronic constipation [115]. So, reduced populations and diversity of Lactobacillus and 













Another interesting result from Wang et al. study [112] was the higher prevalence of P. 
aeruginosa in the fecal samples from PD patients. Pseudomonas is not a very frequent agent 
of gram-negative peritonitis, but it is probably one of the most important causes of severe 
peritonitis in PD patients and is responsible for around 40% of catheter-related infection 
removals [45, 116-118]. However, due to the lack of CKD controls in the study we cannot 
clarify if the alterations in microbial species reported by Wang and colleagues [112] are 
exclusively related to CKD or may be associated to the dialysis therapy. 
As described for HD patients, for PD patients the oral cavity may also represent a starting point 
for dissemination of pathogens through the human body due to the proximity of oral 
microorganisms to the bloodstream [119]. The oral cavity represents a common but transient 
source of microorganisms that may be associated to some routine daily activities or invasive 
dental procedures [119, 120]. Preliminary studies suggest that the oral environment of PD 
patients in comparison to healthy controls may induce changes in oral microbial colonization 
[121].  
As previously stated, gut dysbiosis may impair the intestinal barrier in PD patients promoting 
‘atopobiosis’, namely the translocation of enteric organisms or bacteria-derived toxins to the 
peritoneal cavity by migration through epithelial intestinal barrier. This mechanism may 
represent an important cause of peritonitis in PD patients. The detection of bacterial DNA in 
PD effluent corroborates the hypothesis of ‘apotobiosis’ in PD patients [74, 75, 77]. Moreover, 
our group recently reported the asymptomatic protozoa colonization in peritoneal dialysate of 
PD patients [122], highlighting the magnitude of intestinal translocations in PD patients. And 
so, an additional route for PD-related infections that needs further research is the peritoneal 
microbiome (Figure 1). Recent studies are unravelling microbiome in body sites that were 
previously considered sterile, as the peritoneum. Other examples are the recently revealed 
placenta microbiome [7, 123] and breast tissue microbiome [124]. These studies suggest that 
microorganisms reach these tissues by spreading through hematogenous route. Reinforcing this 
view are the studies recognizing blood microbiome in a non-infectious state [78-82]. 
Preliminary results from our group demonstrated that the peritoneum tissue of CKD patients 
harbours a unique low-abundance microbiome (data not published). 
 
4. Perspectives on patient nutrition and supplements 
The microbiome protection and recovery of HD and PD patients should be an emerging focus 
on future research. Many different strategies are being implemented with variable outcomes. 













microbiome. Prebiotics refer to non-digestible food components that induce the growth or 
activity of beneficial microorganisms in the gut (e.g. bacteria and fungi); probiotics refer to the 
ingestion of living microorganisms and post-biotics refer to the ingestion of the bioactive 
microbial produced molecules.  
The intake of vegetable fibers and some yogurt and cheeses have been described as problematic 
for ESRD patients. Nevertheless, if these foods are supplemented with potassium binding 
resins and phosphate binders they may result in a more balanced gut microbiome in ESRD 
patients [125]. A small trial with HD patients in Belgium evaluated circulating p-cresyl sulfate 
levels following oligofructose-enriched inulin supplementation [126]. The oligofructose-
enriched inulin administration started with 10 g once daily during the first week, at day 8 the 
dose was escalated to 10 g twice daily, and stopped at day 28 after the midweek dialysis session. 
These patients were followed for another 4-week run-out period. Interestingly in these HD 
patients, the oligofructose-enriched inulin supplementation induced a decrease in circulating 
p-cresyl sulfate levels up to the run-out period. Moreover, prebiotic amylose maize resistant 
starch can be metabolized by colon bacteria and produce short-chain fatty acids [127]. A study 
in a CKD rat model showed that a high-fiber diet containing 59% high amylose maize resistant 
starch for 3 weeks retards CKD progression and attenuates oxidative stress and inflammation 
[128]. Fiber supplementation and phytochemical-rich foods can modify the composition of gut 
microbiota, while inulin, fructo-oligosaccharides, galacto-oligosaccharides, soya-
oligosaccharides, xylo-oligosaccharides and pyrodextrins are prebiotics that have been tested 
in CKD patients [125, 126, 129]. 
Probiotics appear to balance intestinal microbiome following massive changes of the initial 
biodiversity and reduce the production of uremic toxins. For example, Lactobacillus 
acidophilus (strains NCFM and BG2F04) [26] and Lebenin (from Wakamoto 
Pharmaceutical, Tokyo, Japan, includes Bifidobacterium longum subsp. infantis, Enterococcus 
faecalis and L. acidophilus) showed to improve health in HD patients by reducing the levels of 
uremic toxins [26, 130]. A formulation of Streptococcus thermophiles (KB19), Lactobacillus 
acidophilus (KB27) and Bifidobacterium longum (KB31) over 3 months was shown to improve 
blood urea nitrogen and quality-of-life in patients with CKD stages 3 and 4 [131]. Data is still 
missing to completely consider the role of synbiotics, a combination of pre and probiotics, in 
CKD patients but a preliminary study showed a reduction of p-cresyl sulfate blood levels and 
Bifidobacterium enrichment and Ruminococcaceae depletion in stools using a symbiotic 













galacto-oligosaccharides together with nine different strains from Lactobacillus, 
Bifidobacteria, and Streptococcus genera [132].  
Recently, the first reports on fecal microbiota transplantation were available showing an 
effective and safe alternative in patients post Clostridium difficile infection [133] but its role in 
the gut of CKD patients still needs to be clarified. 
Other strategies are being tested in CKD patients, as the AST-120 therapy, an adsorbent 
consisting of porous carbon particles capable to adsorb indole in the intestine [134]; sevelamer, 
a large cationic polymer phosphate binder that also binds endotoxins and reduces endotoxin 
and CD14 levels in HD patients [135]; acarbose, an inhibitor of α-glucosidase enzymes in the 
intestinal brush border; among others. However, the particular efficiency of these strategies on 
HD or PD patients still needs to be explored. 
More recently, the microbiome is looked as a therapeutic tool in it-self. “Smart” bacteria [136] 
may guide our immune system, metabolism, and other commensal microorganisms, 
envisioning that targeting and modeling specific microbiota will be the design of personal 
medicine programs in a near future. 
With the constant development of new technologies, one day it will be possible to fully 
understand the function, as well as the existing interactions between microorganisms that 
compose the human microbiota. It can be envisioned that targeting and modeling specific 
microbiota will play a central role in the design of more personalized medicine programs in a 
near future, and vast improvements will be done for disease prevention, diagnosis and therapy. 
 
5. Conclusion 
The ultimate goal of any treatment is to improve the patient’s well-being while preventing the 
development of disease. As they interfere with the human microbiome, some frequent therapies 
may need to be carefully used and/or complemented with additional protective strategies. 
Manipulations of the microbiota can result on changes of the host’s susceptibility to diseases 
and/or affect its severity.  
The specific impact of RRT such as HD or PD on the microbiota imbalance of CKD patients 
is still underexplored. HD and PD have unique characteristics that may contribute to changes 
in the human microbiome, not only restricted to the gut, but also affecting the blood 
microbiome (HD) and the peritoneal microbiome (PD) (Figure 1). Factors promoting these 
changes may be related to specific dietary restrictions and different types of dialysis access 
(vascular vs. peritoneal), as well as the continuous inflow of peritoneal dialysate, containing 













microbiome is still in its infancy. A more interdisciplinary approach is still needed in order to 
better clarify the role of microbial groups other than bacteria and expand the existing research 
to other human microbial habitats. Moreover, strategies to promote a healthier human 
microbiome in these patients should be delineated.  
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Table 1: Dietary intake recommendations for CKD patients, with and without dialysis therapy 
[42, 44]. 
  Non-dialysis patientsa HD PD 
Proteinb  
0.60-0.8 g/kg/d 
 (Low-protein diet) 




35 kcal/kg/d (<60 years old)c 
30 – 35 kcal/kg/d (≥60 years old)c 
Mineral 
Sodium 80-100 mmol/d 
Phosphorus 800-1000 mg and binders if elevated 
Potassium < 1 mmol/kg if elevated 
Not usually  
an issue 
a GFR <30 ml/min/ 1.73 m,2b at least 50% of high biological value; c PD - including kcal from 
dialysate.  
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